as 11-21-2024 4:00pm EST
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | SOLANA BEACH |
Market Cap: | 4.3M | IPO Year: | 2013 |
Target Price: | N/A | AVG Volume (30 days): | 1.2M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.87 | EPS Growth: | N/A |
52 Week Low/High: | $3.54 - $17.40 | Next Earning Date: | 11-07-2024 |
Revenue: | $8,617,036 | Revenue Growth: | 100.35% |
Revenue Growth (this year): | 124.1% | Revenue Growth (next year): | 75.70% |
EVOK Breaking Stock News: Dive into EVOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
GlobeNewswire
15 days ago
Simply Wall St.
18 days ago
GuruFocus.com
25 days ago
MT Newswires
25 days ago
MT Newswires
25 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
The information presented on this page, "EVOK Evoke Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.